Authors:
Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, et al.
Authors notes:
Journal of Infectious Diseases. 2013;208(9):1391-1396
Keywords:
Genital warts, HPV, HPV vaccine, human papillomavirus
Abstract:
Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008.
A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent.
In the TVC naive cohort, VE against 6MPI was 34.5% for HPV-6/11, 34.9% for HPV-6, 30.3% for HPV-11, and 49.5% for HPV-74.
The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed.
These findings may help to explain the decrease in external GW diagnoses seen in England.